Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
Study Details
Study Description
Brief Summary
This is a randomized, double-blind, placebo-controlled study of RP7214 in patients with symptomatic mild SARS-CoV-2 infection, having at least one high-risk feature (e.g., age > 60 years, hypertension, diabetes mellitus, chronic lung disease, chronic kidney disease, liver disease, cerebrovascular disease, obesity, cancer) for developing severe Covid-19 illness.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: RP7214 + Standard of care (SOC)
|
Drug: RP7214 + Standard of care (SOC)
RP7214 tablets will be administered orally twice a day for 14 days
|
Placebo Comparator: Placebo + Standard of care (SOC)
|
Drug: Placebo + Standard of care (SOC)
Placebo will be administered orally twice a for 14 days
|
Outcome Measures
Primary Outcome Measures
- Proportion of patients requiring Covid-19 related hospitalization by Day 15. [15 days]
Secondary Outcome Measures
- Change from baseline in SARS-CoV-2 viral load at Days 3, 7 and 15 by quantitative RT-PCR test [15 days]
- Time to symptom resolution in patients receiving RP7214 as compared to placebo [15 days]
- Proportion of patients demonstrating symptom resolution [15 days]
- Time to symptom improvement in patients receiving RP7214 as compared to placebo [15 days]
- Proportion of patients demonstrating symptom improvement [15 days]
- Adverse Events (AEs) as assessed by laboratory tests, vital signs and physical examination. [15 days]
- Change in the disease-specific inflammatory markers (Ferritin, C-reactive protein (CRP), D-dimer, neutrophil to lymphocyte/CD8+ ratio, LDH, IL-6) as compared to baseline. [15 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Willing and able to provide informed consent.
-
Males and females of ≥ 18 years of age
-
Patient with mild COVID-19 infection having ≥ 1 symptoms.
-
Laboratory confirmed Covid-19 infection by Reverse Transcription Polymerase Chain Reaction (RT-PCR) in nasopharyngeal sample (within 72 hours prior to randomization).
-
Patient should have at least one pre-existing high-risk feature for developing severe Covid-19 illness.
-
Ability to swallow and retain oral medication.
-
Male patient who is surgically sterile, or who is willing to agree to use a contraceptive measure.
-
Women of childbearing potential should be willing to use a medically acceptable method of contraception.
-
Willing to receive telephone calls or have videoconferences with study team personnel.
-
Willing and able to understand the nature of this study, comply with the study procedures and follow-up procedures as per the study protocol.
Exclusion Criteria:
-
Patient with asymptomatic Covid-19 infection.
-
Patient who has experienced the onset of any of Covid-19 symptoms > 5 days at the time of randomization.
-
Moderate to Severe COVID-19 infection
-
Patient with Covid-19 re-infection
-
Subjects who are severely immunocompromised
-
Subjects with autoimmune diseases
-
Patients with any bleeding disorder e.g., hemophilia and von Willebrand disease.
-
Current use of other DHODH inhibitors including teriflunomide or leflunomide.
-
Patients who are on or immediately require Covid-19 directed treatment such as antivirals, immunomodulatory treatment, convalescent plasma, oral/ intravenous steroids, or monoclonal antibodies at the time of screening.
-
Patients who have had received one or two doses of vaccine for Covid-19.
-
Patients participating in another clinical study or use of any investigational product within 4 weeks or 5 half-lives of the drug, whichever is longer, before the date of dosing
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Citizen Hospital | Bangalore | India | ||
2 | Madhu Superspeciality Hospital & Research Center | Bangalore | India | ||
3 | Rajalakshmi Hospital & Research Center | Bangalore | India | ||
4 | Panimalar medical college hospital and research institute | Chennai | India | ||
5 | Maharaja Agrasen Superspeciality Hospital | Jaipur | India | ||
6 | Nil Ratan Sircar Medical College and Hospital | Kolkata | India | ||
7 | Malabar Medical College | Kozhikode | India | ||
8 | BAJ RR Hospital & Research center | Mumbai | India | ||
9 | DEC Healthcare Hospital | Nellore | India | ||
10 | Vijaya Super specialty Hospital | Nellore | India | ||
11 | Jivanrekha Multispeciality Hospital | Pune | India | ||
12 | PCMC'S PGI Yashwantrao Chavan Memorial Hospital | Pune | India | ||
13 | Sant Dnyaneshwar Hospital (Accord Multispeciality Hospital) | Pune | India | ||
14 | Govt General Hospital | Srikakulam | India | ||
15 | Great Eastern medical school and hospital | Srikakulam | India | ||
16 | King George Hospital | Visakhapatnam | India |
Sponsors and Collaborators
- Rhizen Pharmaceuticals SA
- Incozen Therapeutics Pvt Ltd
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RP7214-2101